University of California, San Francisco

ŌURA Acquires Proxy in All-Equity Deal

Retrieved on: 
Tuesday, May 9, 2023
Luxury, Women, Consumer Electronics, Technology, Men, Other Retail, General Health, Specialty, Mobile, Wireless, Consumer, Retail, Health Technology, Biometrics, Fitness & Nutrition, Jewelry, Software, Health, Wearables, Mobile Technology, Hardware, Other Consumer, Online Retail, Partnership, University, Culture, Public, University of California, San Francisco, COVID-19, Sleep, Research, Privacy, University of California, San Diego, Natural Cycles, Literature, Digital technology, Strava, Acquisition, Best Buy, Growth, Hustling, Mental health, Online shopping, Cryptocurrency, Proxy

ŌURA, the company behind the smart ring that delivers personalized health data, insights, and daily guidance, announced its acquisition of Proxy, best known for its digital identity signal platform, in an all-equity deal.

Key Points: 
  • ŌURA, the company behind the smart ring that delivers personalized health data, insights, and daily guidance, announced its acquisition of Proxy, best known for its digital identity signal platform, in an all-equity deal.
  • Proxy has been in stealth mode, working to advance its biometrically-linked digital technology from mobile phones to wearables.
  • This deal expands ŌURA’s leadership in health wearables and signals our ambitions to integrate digital identity technology with our existing hardware and software offerings,” said Tom Hale, ŌURA CEO.
  • By joining ŌURA, the smart ring leader, we can change the game.”
    The transaction is subject to customary closing conditions.

Nippon Life Selects H2O.ai to Transform Its Insurance Business With Machine Learning and Improve Customer Health

Retrieved on: 
Wednesday, May 3, 2023
Technology, Insurance, Fitness & Nutrition, Professional Services, Software, Internet, Health, Data Management, Artificial Intelligence, Cloud, AT&T, Partnership, University, Document AI, Chief of Policy and Plans Department, University of California, San Francisco, Health promotion, Intelligence, Document, Forecasting, Algorithm, Heel, Machine learning, News, Automation, Data science, Medical device, Nippon Life

H2O.ai , the AI Cloud leader, today announced a strategic partnership with Nippon Life Insurance Company, also known as Nissay in Japan.

Key Points: 
  • H2O.ai , the AI Cloud leader, today announced a strategic partnership with Nippon Life Insurance Company, also known as Nissay in Japan.
  • Specifically, the companies are announcing a partnership where Nippon Life Insurance Company will deploy H2O Driverless AI tools to better meet the needs of their policyholders, improve financial soundness of corporate health insurance unions and support health promotion and disease prevention.
  • “AI is transforming the trillion dollar healthcare insurance industry, both the businesses themselves and the care they facilitate,” said Sri Ambati, CEO and founder of H2O.ai.
  • “By helping Nippon Life advance their AI initiatives and create better customer experiences, the end result is literally, healthier people.

Curve Biosciences Appoints Industry Veterans to Leadership Team, Announces Commercial Advisory Board

Retrieved on: 
Wednesday, May 3, 2023
Health, Technology, Other Health, Software, General Health, Research, Science, Acumen, Insurance, Communication, CDTA, Aetna, Marketing, Stanford University, Longevity, Doctor of Philosophy, GRAIL, Genetics, MD, Patient, Conditional sentence, Commercial Operating System, San Francisco, Tissue, University, CSO, Inflammatory bowel disease, Burns, DaVita Inc., Medicine, Chronic condition, Biology, Liver, Cancer, Electrical engineering, Data mining, Biomarker, CVS Health, Chronic liver disease, UnitedHealth Group, Electricity, Endometriosis, University of California, San Francisco, Human Longevity, Genomics, Trial of the century, Biological engineering, World Health Organization, Management, Medical imaging, Pharmaceutical industry, Myriad Genetics, Natera, Curve

“Chuba and Nathan have created, launched, and scaled multiple products, including in early disease detection,” said Ritish Patnaik, PhD , CEO of Curve.

Key Points: 
  • “Chuba and Nathan have created, launched, and scaled multiple products, including in early disease detection,” said Ritish Patnaik, PhD , CEO of Curve.
  • She previously was vice president of Commercial Operations at Counsyl, and held leadership roles at DaVita and MyHealthTeam.
  • He previously held the same role at Serimmune, Inc., and held commercial leadership roles at Human Longevity, Counsyl, AltheaDx and Verinata.
  • We look forward to working with our advisors to maintain our progress and explore commercial opportunities in other chronic diseases.”

ŌURA Welcomes Four Experts to Newly Appointed Medical Advisory Board

Retrieved on: 
Tuesday, May 2, 2023
Wearables, Mobile Technology, Apps, Applications, Technology, Fitness & Nutrition, Biometrics, Health, General Health, Data Management, Consumer Electronics, Partnership, Pregnancy, University, Friends, Public, University of California, San Francisco, COVID-19, Sleep, Oura Health, University of California, San Diego, Research, CNBC, Natural Cycles, Literature, Esquire, Best Buy, Oura, Invention, Fertility, Menopause, FDA, Mental health, Cybook Gen3, Canada Fitness Award Program, Pharmaceutical industry, Science

The Medical Advisory Board will consist of Dr. Kiarra King , Dr. Rebecca Robbins , Dr. Christine Noa Sterling , and Dr. Matthew Walker , with plans to add new members in the coming months.

Key Points: 
  • The Medical Advisory Board will consist of Dr. Kiarra King , Dr. Rebecca Robbins , Dr. Christine Noa Sterling , and Dr. Matthew Walker , with plans to add new members in the coming months.
  • “ŌURA’s health sensing capabilities and products have been grounded in science since its inception 10 years ago, and we are strengthening that foundation today with the formation of our Medical Advisory Board,” said Shyamal Patel, Head of Science at ŌURA.
  • “We have so much to be proud of since ŌURA was founded by a small team in Finland in 2013,” said Tom Hale, ŌURA CEO.
  • To learn more about ŌURA and the newly formed Medical Advisory Board, visit http://www.ouraring.com/medical-advisory-board .

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Retrieved on: 
Friday, April 28, 2023
Human, Software as a service, University, Neck pain, Low back pain, Spine, University of California, San Francisco, Scoliosis and Spinal Disorders, Biomarker, ACON, Doctor of Philosophy, Pain, CO, MD, Patient, Physician, Algorithm, Diagnosis, Orthopedic surgery, VIP, Medical imaging, Nursing, Dentistry

BROOMFIELD, CO, April 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today they are hosting an Aclarion Symposium at SPINEWEEK 2023 in Melbourne, Australia. Aclarion executives Brent Ness and Ryan Bond will be joined by renowned spine industry experts Sigurd Berven, MD and Jeff Lotz, PhD, both of whom will present important information about Aclarion’s foundational science and groundbreaking clinical evidence.

Key Points: 
  • BROOMFIELD, CO, April 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today they are hosting an Aclarion Symposium at SPINEWEEK 2023 in Melbourne, Australia.
  • The Aclarion Symposium will be held on Tuesday, May 2, 12:30-14:00 in VIP Suite 2 at the Melbourne Convention Exhibition Centre.
  • “We are pleased to support the global thought leadership fostered by SPINEWEEK and we are honored to have luminaries such as Dr. Lotz and Dr. Berven presenting important Aclarion evidence to this global audience.
  • Aclarion is committed to leading with clinical and economic evidence, and we look forward to participating in SPINEWEEK this year,” said Brent Ness, CEO, Aclarion.

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

Retrieved on: 
Monday, May 1, 2023
Science, Neurology, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, San Francisco, Critical care, University, Novel Therapeutic Targets for Antiarrhythmic Drugs, AABB, Critical, Colorado State University, Stroke, University of California, San Francisco, TBI, Regenerative medicine, DOD, DARPA, Patient, Blood, Transfusion medicine, FDA, SCI, Therapy, BARDA, NIH, Pharmaceutical industry, Medical device, Trauma, Polytrauma

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.
  • Presented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options.
  • This conference will bring together the expertise and input of cell therapy companies, clinicians, basic scientists, industry, FDA, NIH, AABB, DARPA, BARDA and DOD representatives to discuss current research and existing barriers in the translation of these novel therapies in trauma and critical care medicine.
  • Dr. Willie Mays, Executive Vice President and Head of Regenerative Medicine and Neuroscience Programs, has been invited to participate in this conference.

Study Suggests Catalyst for Human Brain Evolution

Retrieved on: 
Friday, April 28, 2023
San Francisco, DNA, Human, Biotechnology, Data science, Mammal, University of California, San Francisco, Brain, HARS, Cell, Doctor of Philosophy, UC, Gladstone Institutes, Primate, SAN, Blood, Pollard, B cell, Gene, Chimpanzee, Genome, Vaccine, Hunting, Science, William Ewart Gladstone

SAN FRANCISCO, April 28, 2023 /PRNewswire/ -- More than a million years ago, large chunks of the human genome were rearranged—a chance event during egg or sperm formation that led to the deletion, duplication, or reversal of sections of DNA. Those structural variants, researchers have now discovered, likely set off a cascade of other rapid changes in human DNA that may underlie uniquely human features, particularly the brain.

Key Points: 
  • Those structural variants, researchers have now discovered, likely set off a cascade of other rapid changes in human DNA that may underlie uniquely human features, particularly the brain.
  • The new finding, published today in Science by researchers at Gladstone Institutes, came out of a study analyzing how stretches of DNA called human accelerated regions (HARs) differ between humans and chimpanzees.
  • Researchers have long wondered why these sequences—many of which control brain development—changed so rapidly in early human evolution.
  • Her lab has since shown that most HARs are enhancers, short stretches of DNA that regulate the activity of genes related to brain development.

ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF

Retrieved on: 
Wednesday, April 26, 2023
US Foods, Drug development, University, SIV, University of California, San Francisco, ADHD, Attention deficit hyperactivity disorder, Doctor of Philosophy, CNS, Trial of the century, Plant, Patient, UCSF, Medical Center, Ophthalmology, Phase, Grandview, Pharmaceutical industry, Neuroscience

The UCSF site, led by Professor Keith McBurnett, PhD, at the UCSF Weill Institute for Neurosciences, will join five other Taiwan sites for ABVC BioPharma’s Phase II Part 2 clinical study in patients with ADHD.

Key Points: 
  • The UCSF site, led by Professor Keith McBurnett, PhD, at the UCSF Weill Institute for Neurosciences, will join five other Taiwan sites for ABVC BioPharma’s Phase II Part 2 clinical study in patients with ADHD.
  • The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II” is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan.
  • The Phase II Part 2 clinical study is a continuation of the Phase II Part 1 clinical study of ABV-1505, which was completed successfully by achieving the specified primary endpoints at UCSF and accepted by the US Food & Drug Administration in October of 2020.
  • “We are pleased to have Professor Keith McBurnett leading the UCSF team to perform ADHD Phase II Part 2 study,” said Dr. Howard Doong, ABVC BioPharma’s Chief Executive Officer.

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, San Francisco, Drug development, University, Internal medicine, AbbVie, Stanford University, Oregon Health & Science University, Anosy, Roche, University of California, San Francisco, Cancer, Antibody, Strategic planning, Chugai Pharmaceutical Co., Oregon Health and Science University Center for Women's Health, Patient, UCSF, Physician, Hematology, Protein engineering, Cytokine, Nursing, Genentech

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.
  • In her new role, effective May 1, 2023, she will be responsible for leading Xencor’s clinical and medical strategy and execution.
  • Allen Yang, M.D., Ph.D., Chief Medical Officer, will continue to advise the Company and after a transition period will leave Xencor to pursue other opportunities.
  • “During her time on our Board, Nancy gained a deep understanding of our XmAb® platforms, portfolio strategy, development programs, and people, and we are delighted that she has chosen to join our senior management team,” said Bassil Dahiyat, Ph.D., President and Chief Executive Officer at Xencor.

Thermo Fisher Scientific Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023
Science, Other Science, Research, San Francisco, Partnership, Food, University, Applied Biosystems, Drink, Table, University of California, San Francisco, COVID-19, TMO, GAAP, Thermo Fisher Scientific, Binding site, COVID-19 testing, Element, Acquisition, Soil, UCSF, CGMP, Water, Invitrogen, EPS, PPI, Mindful Scientific Inc., NYSE, PCR, Management, Video game, Pharmaceutical industry

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.
  • GAAP operating income for the first quarter of 2023 was $1.56 billion, compared with $2.82 billion in the year-ago quarter.
  • Adjusted operating income for the first quarter of 2023 was $2.33 billion, compared with $3.45 billion in the year-ago quarter.
  • Thermo Fisher Scientific will hold its earnings conference call today, April 26, 2023, at 8:30 a.m. Eastern Time.